Collegium Pharmaceutical: Modest Valuation Makes It Worthwhile To Monitor Xtampza Sales Trajectory – Seeking Alpha


Seeking Alpha
Collegium Pharmaceutical: Modest Valuation Makes It Worthwhile To Monitor Xtampza Sales Trajectory
Seeking Alpha
Collegium Pharmaceutical (COLL) has come under some pressure last week. Worries about a slower roll-out of Xtampza, potential increased competition and concerns about additional shares being issued, created a cocktail of bad news for equity investors.

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd